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Chronic heart failure (CHF) is an increasingly large medical
and epidemiological problem, associated with a high mor-
bidity and mortality. Until recently, angiotensin-converting
enzyme inhibitors, in combination with diuretics, were the
cornerstone in the treatment of CHF. In many patients,
digoxin was also part of the standard treatment, and it was
assumed that digoxin would be of additional (long-term)
benefit in these patients. Results of the Digitalis Investiga-
tion Group (DIG) trial, however, have shown that, al-
though digoxin caused a 6% reduction in overall hospital-
izations, it did not affect mortality (1). This somewhat
disappointing result would “conclude the debate on digital-
is,” as Dr. Packer commented in his accompanying editorial
(2). He pointed out that digoxin’s inability to substantially
reduce morbidity and mortality would eliminate a mandate
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for its use, as the list of other drugs that—in contrast to
digoxin—had shown such an effect would increase. Obvi-
ously, the latter particularly applies to beta-blockers, which
in recent years have been proven to cause a significant and
clinically relevant reduction in both morbidity and mortal-
ity. Because of these favorable findings, beta-blockers are
rapidly becoming part of the standard treatment of CHF,
and in recent guidelines a prominent role for these drugs is
reserved in all classes of CHF (3). As a result, the relative
importance of digoxin will probably further diminish, al-
though data showing a decline in its use are not yet
available. Assuming that the place of digoxin in patients
with CHF and atrial fibrillation is (still) unquestioned (3),
uncertainty remains regarding the place of digoxin in the
treatment of patients with CHF and sinus rhythm.
The study by Adams et al. (4) in this issue of the Journal
provides important new information on this subject. These
investigators have re-analyzed data from two digoxin with-
drawal studies: the Prospective Randomized study Of Ven-
tricular function and Efficacy of Digoxin (PROVED) (5)
and the Randomized Assessment of Digoxin and Inhibitors
of ANgiotensin-Converting Enzyme (RADIANCE) (6).
Their primary objective was to investigate the relation
between serum digoxin concentrations (SDCs) in the two
trials and the end points of clinical efficacy, in particular the
rate of worsening CHF, change in left ventricular ejection
fraction (LVEF), and change in treadmill time.
For this purpose, patients were divided at randomization
into four groups: one group consisted of those who discon-
tinued digoxin (placebo group), and the three other groups
were patients who were divided according to their SDC at
randomization. The latter three groups had the following
characteristics: lowest tertile (33 percentile, 0.9 ng/ml,
mean 0.78  0.02 ng/ml); middle tertile (33 to 66 percen-
tile, 0.9 to 1.2 ng/ml, mean 1.09 0.01 ng/ml); and highest
tertile (66 percentile, 1.2 ng/ml, mean 1.52  0.03
ng/ml). The principal finding of the Adams et al. (4) study
was that, whereas patients in all three digoxin groups
generally fared better than those on placebo, multiple
regression analysis showed there was no relationship be-
tween randomization SDC and any of the study end points.
In other words, there was no difference among the three
“digoxin groups” during the study. Importantly, patients in
the low SDC category performed significantly better (p 
0.05) on all clinical end points compared to those in whom
digoxin was discontinued: they were less likely to experience
worsening CHF, and both their LVEF and treadmill
exercise times were significantly higher.
This result is important and deserves attention as it may
have clinical implications. It is unlikely that many new data
on digoxin will become available in the next few years, and
many CHF patients around the world are still using the
drug. The present data must therefore be examined care-
fully, and some limitations to the Adams et al. (4) study
must be discussed. The major limitation of their study is
obviously the way the data were collected: the two original
studies had a withdrawal design; also, for the present
analysis, patients were not randomly assigned to the three
SDC groups. The limitations of the withdrawal design are
well known, but also the three groups were divided by SDC,
and not by different doses of digoxin. Indeed, Table 2 in the
Adams study shows that there was no difference in digoxin
doses among groups. This means that, with the same dose,
different SDCs were reached, which may suggest that in the
“high” SDC group, the drug accumulated as a result of a
clearance problem, in particular renal dysfunction. Although
many clinical variables were included in the investigators’
multivariate analysis, renal function was not among them
(see also their Table 1), and given the fact that this
parameter has been shown to be one of the most powerful
predictors of prognosis in CHF (7), and also in the DIG
database (8), the difference in SDC may have been (partly)
a reflection of differences in renal function. One might thus
speculate that a possible benefit of the higher dose could
have been offset by the more impaired renal function (and
more advanced CHF).
Another problem with the design is that after eligibility
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was confirmed, patients were uptitrated before randomiza-
tion to doses that corresponded to SDCs of 0.9 to 2.0
ng/ml. In the highest tertile this led to a SDC of 1.52 
0.08 ng/ml at the beginning of the study, but it had dropped
to 1.25 0.08 ng/ml at the end of the study, which was not
so different anymore from the SDC at the end of the study
in the “middle” tertile (1.14  0.09 ng/ml). In other words,
if a true difference in clinical effect would be present among
the three SDC groups, such a small difference in the actually
measured SDC during the study would make it less likely
that a clinical difference would surface.
The other main limitation of the Adams et al. study is the
small sample size together with the short follow-up; partic-
ularly, if the digoxin group is broken up in three groups,
only small groups of (40 to 50) patients remain. This leads
to few clinical events, and one wonders whether the 6%
dropout during the 12-week study in the “low” SDC group
would have led to a significant difference between this group
and the “middle” (9%) and “high” tertile (12%) SDC groups
had the number of patients been higher or the follow-up
longer.
The main finding of the Adams et al. report is that
patients with low SDCs perform at least as well as those
with higher SDCs. In two earlier and fairly large trials with
milrinone (9) and pimobendan (10), higher SDC levels were
associated with increased mortality, particularly when SDCs
were 1.0 ng/ml; however, in both trials positive inotropic
drugs were examined, and the untoward effects of digoxin
may have been increased in this setting.
The data of the DIG study could also be very important
in this respect, as it is also referred to in the present study
(4). In the main publication this is not discussed (1), but in
a letter to the editor this was pointed out (11) to which the
authors responded that “there was no relation between
digoxin levels and clinical efficacy . . . , but that [this anal-
ysis] is potentially confounded . . . [by other variables]” (12).
Interestingly, in a review paper discussing the DIG trial,
Gheorghiade and Pitt (13) state that “in the DIG trial there
was an association between serum concentration and mor-
tality” and they continue that “this finding was observed
even at serum concentrations within the so-called therapeu-
tic range” (13). Given this confusion, and the clinical
relevance of the problem, I strongly believe that a proper
multivariate analysis (including also renal function and
concomitant drug use) should be conducted to assess the
relation between clinical outcome and SDCs in the 1,485
patients in the DIG trial in whom they were measured.
In the DIG trial, the mean one-month SDC for all
digoxin patients was 0.86 ng/ml (1). When related to
specific dose, SDC values for 0.125 mg (17.5% of the
population), 0.25 mg (70.3%), 0.375 mg (10.8%), and
0.50 mg (1.0%) were 0.76 ng/ml, 0.89 ng/ml, 0.88 ng/ml,
and 0.88 ng/ml, respectively. At one month, 88.3% of all
patients had SDCs within the “therapeutic range” of 0.5 to
2.0 ng/ml, and only 2% had SDC levels 2.0 ng/ml.
However, 20% of patients had SDC levels of 1.0 to
1.5 ng/ml, and 5% of patients had SDCs of 1.5 to 2.0 ng/ml
(Dr. Richard Gorlin, oral presentation at the 45th American
College of Cardiology Sessions, Orlando, Florida, March
1996). One may thus conclude that the dosing regimen
worked well for the prespecified margins that were assumed
optimal at the time the DIG trial was designed (1990).
However, since then, data have emerged, including those
reported in the present study (4), and in others discussed
above, that SDC levels above 1.0 ng/ml are not leading to
additional benefit, and in fact may be harmful, and should
thus be avoided. In light of this finding, 27% of all patients
may have had too high SDCs, which may have significantly
and negatively affected the outcome.
Increasing evidence shows a dissociation between the
neurohormonal effects of digoxin that are achieved at low
SDCs and the hemodynamic (positive inotropic) effects that
mainly emerge at higher SDC levels (13–16). Because the
neurohormonal effects of digoxin are generally assumed to
be beneficial, and the positive inotropic effect should prob-
ably be minimalized if evident at all, this would also be a
mechanistic explanation of why relatively lower doses of the
drug should be preferred.
The only way to truly investigate whether lower doses of
digoxin are better than higher doses is to conduct a
prospective, randomized, placebo-controlled study with suf-
ficient power. Such a mortality study should also stratify for
beta-blocker use at baseline; because these agents are now
used on a large scale, they may significantly affect outcome
in CHF, and they may possibly enhance the effect of
digoxin (13).
With regard to the design of such a study, a placebo-
controlled trial would probably be feasible nowadays, and
the high- versus low-digoxin groups should be divided by
SDC rather than by dose. The DIG study has made clear
that an algorithm is able to guide SDCs, and also SDC
levels remain rather stable over time (1). Conversely, it has
also been made clear that even with low doses of digoxin,
SDC levels 1.0 ng/ml are often reached. This may well be
related to the presence of renal dysfunction in such a CHF
population. In the DIG trial, serum creatinine concentra-
tions 1.7 mg/dl were found in only 5% of patients 50
years old, but this increased to 30% of patients 80 years
old (8). The target dose in such a trial should probably be
0.5 to 1.0 ng/ml, although sufficient data about the mini-
mum required dose are scarce. In the DIG study, 12% of
patients had SDCs 0.5 ng/ml (Dr. Richard Gorlin, ACC
1996), and it would be useful to examine this subgroup of
patients.
What should be the next step in the research regarding
digoxin in CHF, and do we need further investigation into
this issue? Given the fact that vast numbers of patients are
still taking the drug, and that many questions still remain,
the answer to this, in my opinion, must be positive. The first
thing that could be done relatively easy would be to examine
more thoroughly the dose (SDC) issue in the DIG trial. To
obtain a convincing answer, I believe a second mortality
955JACC Vol. 39, No. 6, 2002 van Veldhuisen
March 20, 2002:954–6 Editorial Comment
study is required. Whether such a trial will ever be con-
ducted is doubtful, however. Investigators are generally less
inclined to further analyze results of clinical trials with a
negative or neutral outcome such as DIG, and of course this
reluctance applies even more to designing a second trial in
the same field as the first (negative) trial (17).
In addition, digoxin is an inexpensive drug, and a large
mortality study is a very expensive and uncertain project. For
this reason, it is not very likely that a pharmaceutical
company will embark on such a project. The only way to
conduct such a study would probably be through “non-
pharmaceutical” grants, derived from local or national
health foundations, or large organizations such as the
National Institutes of Health. In a world where cost-benefit
considerations play an increasingly important role, health
policymakers should seriously consider such an option.
In conclusion, despite limitations, the present data pro-
vide further support for the suggestion that low SDC levels
might be superior to higher SDC levels in patients with
CHF. I hope these data will provide a new stimulus to
investigate the potential place of this drug in CHF. This can
be accomplished by several lines of research, of which
further analysis of the DIG database would seem useful. To
obtain true and convincing answers, however, I believe a
second digoxin mortality trial in CHF, targeted at lower
SDC levels (0.5 to 1.0 ng/ml), must be seriously considered.
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